用于心肌缺血再灌注损伤靶向治疗的先进纳米材料平台
Advanced Nanomaterial Platforms for Targeted Therapy of Myocardial Ischemia-Reperfusion Injury.
作者信息
Wang Hanxi, Li Li, Luo Lihan, Cheng Yuqi, Zhou Feng, Zhao ShuangJun, Li Yang, Yang Yuzhu, Zhou Qianqian, Niu Hanyun, He Jiannan, Zhang Cao, Guo Jian, Tang Longguang, Xu Jianhong
机构信息
Department of Anesthesiology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
出版信息
Research (Wash D C). 2025 Aug 5;8:0822. doi: 10.34133/research.0822. eCollection 2025.
Ischemic heart disease (IHD) remains a major global health challenge due to its persistently high incidence and mortality rates. Although early thrombolytic or interventional therapy reduces infarct size, myocardial ischemia-reperfusion injury (MIRI) often occurs when restoring blood flow to ischemic myocardium, paradoxically causing cardiomyocyte death. Unlike conventional cardioprotective agents, bioengineered nanomaterials enable targeted drug delivery to ischemic cardiomyocytes through tunable physicochemical properties. This improves therapeutic efficacy while reducing systemic exposure, providing innovative strategies for MIRI treatment. This review summarizes recent advances in nanomaterial-based MIRI therapies and critically evaluates their clinical translation potential, highlighting both opportunities and challenges.
由于缺血性心脏病（IHD）的发病率和死亡率持续居高不下，它仍然是全球主要的健康挑战。尽管早期溶栓或介入治疗可缩小梗死面积，但在恢复缺血心肌血流时，心肌缺血再灌注损伤（MIRI）常常发生，反常地导致心肌细胞死亡。与传统的心脏保护剂不同，生物工程纳米材料能够通过可调节的物理化学性质将药物靶向递送至缺血心肌细胞。这提高了治疗效果，同时减少了全身暴露，为MIRI治疗提供了创新策略。本综述总结了基于纳米材料的MIRI治疗的最新进展，并严格评估了它们的临床转化潜力，突出了机遇和挑战。
Zotero 插件